瑞孚迪2025年财报：营收同比增长3.7%

Core Viewpoint - Revvity reported a total revenue of $2.856 billion for 2025, reflecting a year-on-year growth of 3.7% [2][4]. Financial Performance Overview 2025 Fourth Quarter Performance - The GAAP earnings per share (EPS) for Q4 2025 was $0.87, compared to $0.78 in the same period last year [3]. - Q4 revenue reached $772 million, up from $729 million year-on-year, marking a growth of 5.9% [3][11]. - The GAAP operating profit from continuing operations was $111.7 million, with an operating profit margin of 14.5%, down from 16.3% in the previous year [3][11]. 2025 Full Year Performance - For the full year 2025, the GAAP EPS was $2.07, down from $2.20 in 2024 [4]. - Total revenue for 2025 was $2.856 billion, an increase from $2.755 billion in 2024, representing a growth of 3.7% [4]. - The GAAP operating profit for continuing operations was $357 million, with a profit margin of 12.5% [4]. Business Segment Performance Life Sciences Segment - The Life Sciences segment generated $1.431 billion in revenue for 2025, up from $1.399 billion in 2024, reflecting a growth of 2% [6][8]. - Q4 revenue for the Life Sciences segment was $382 million, compared to $375 million in the same quarter last year, indicating a growth of 2% [7]. Diagnostics Segment - The Diagnostics segment reported $1.425 billion in revenue for 2025, an increase from $1.356 billion in 2024, representing a growth of 5% [8]. - Q4 revenue for the Diagnostics segment was $390 million, up from $355 million year-on-year, showing a significant growth of 10% [9]. 2026 Financial Guidance - The company forecasts total revenue for fiscal year 2026 to be between $2.96 billion and $2.99 billion, with an organic revenue growth rate of 2% to 3% [13]. - Adjusted EPS for 2026 is projected to be between $5.35 and $5.45 [13].